Next generation medical therapy for Cushing's Syndrome-can we measure a benefit?
Authors
Trainer, Peter JAffiliation
The Christie NHS Foundation Trust, Manchester M20 4BX, United KingdomIssue Date
2014-04
Metadata
Show full item recordCitation
Next generation medical therapy for Cushing's Syndrome-can we measure a benefit? 2014, 99 (4):1157-60 J Clin Endocrinol MetabJournal
The Journal of Clinical Endocrinology and MetabolismDOI
10.1210/jc.2014-1054PubMed ID
24702012Type
ArticleLanguage
enISSN
1945-7197ae974a485f413a2113503eed53cd6c53
10.1210/jc.2014-1054
Scopus Count
Collections
Related articles
- Pharmacotherapy: a new option for Cushing disease?
- Authors: Heath V
- Issue date: 2014 Mar
- LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
- Authors: Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH, Boscaro M, Biller BM
- Issue date: 2014 Apr
- Osilodrostat (Isturisa) for Cushing's disease.
- Issue date: 2021 Feb 8
- Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
- Authors: Fontaine-Sylvestre C, Létourneau-Guillon L, Moumdjian RA, Berthelet F, Lacroix A
- Issue date: 2021 Apr
- Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas.
- Authors: Tabarin A, Haissaguerre M, Lassole H, Jannin A, Paepegaey AC, Chabre O, Young J
- Issue date: 2022 Jan 6